These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38658364)

  • 1. Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review.
    Zhao F; Lu H
    Biosci Trends; 2024 Jun; 18(2):141-152. PubMed ID: 38658364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures.
    Ritou E; Satta S; Petcherski A; Daskou M; Sharma M; Vasilopoulos H; Murakami E; Shirihai OS; Kelesidis T
    Metabolism; 2023 Apr; 141():155395. PubMed ID: 36842771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV.
    Damas J; Munting A; Fellay J; Haerry D; Marzolini C; Tarr PE; Steffen A; Braun DL; Stoeckle M; Bernasconi E; Nawej Tshikung O; Fux CA; Darling KEA; Béguelin C; Wandeler G; Cavassini M; Surial B;
    Clin Infect Dis; 2024 Oct; 79(4):990-998. PubMed ID: 38606792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir alafenamide nephrotoxicity: a case report and literature review.
    Ueaphongsukkit T; Gatechompol S; Avihingsanon A; Surintrspanont J; Iampenkhae K; Avihingsanon Y; Udomkarnjananun S
    AIDS Res Ther; 2021 Aug; 18(1):53. PubMed ID: 34419091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials.
    Pilkington V; Hughes SL; Pepperrell T; McCann K; Gotham D; Pozniak AL; Hill A
    AIDS; 2020 Dec; 34(15):2259-2268. PubMed ID: 33048869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report.
    Heron JE; Bloch M; Vanguru V; Saunders J; Gracey DM
    BMC Nephrol; 2020 Aug; 21(1):339. PubMed ID: 32787843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
    Campbell L; Barbini B; Burling K; Cromarty B; Hamzah L; Johnson M; Jones R; Samarawickrama A; Williams D; Winston A; Post FA;
    J Acquir Immune Defic Syndr; 2021 Oct; 88(2):214-219. PubMed ID: 34506361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil.
    Campbell L; Barbini B; Cromarty B; Hamzah L; Williams D; Winston A; Post FA;
    AIDS; 2024 Jul; 38(9):1442-1445. PubMed ID: 38932750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.
    Kauppinen KJ; Kivelä P; Sutinen J
    AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
    Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
    AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir alafenamide fumarate.
    Lee WA; Cheng AK
    Antivir Ther; 2022 Apr; 27(2):13596535211067600. PubMed ID: 35499175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.
    Łomiak M; Stępnicki J; Mikuła T; Wiercińska-Drapało A
    Int J STD AIDS; 2021 May; 32(6):570-577. PubMed ID: 33612018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
    Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
    Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
    Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tenofovir alafenamide fumarate - a new generation of tenofovir].
    Snopková S; Havlíčková K; Husa P
    Klin Mikrobiol Infekc Lek; 2016 Sep; 22(3):111-117. PubMed ID: 27907972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir alafenamide use in pregnant and lactating women living with HIV.
    Eke AC; Brooks KM; Gebreyohannes RD; Sheffield JS; Dooley KE; Mirochnick M
    Expert Opin Drug Metab Toxicol; 2020 Apr; 16(4):333-342. PubMed ID: 32125906
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
    Surial B; Cavassini M; Calmy A; Fehr J; Stöckle M; Bernasconi E; Roth B; Fux CA; Kovari H; Furrer H; Rauch A; Wandeler G;
    BMC Infect Dis; 2019 Oct; 19(1):834. PubMed ID: 31601174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.